| Gene symbol | tk |
| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC0387 |
| Trial ID | NCT03281382 |
| Disease | Pancreatic Cancer |
| Altered gene | E1|IL-12A|IL-12B|yCD|SR39|tk |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | AdV5-yCD/mutTKSR39rep-hIL12 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | PHASE 1 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED CYTOTOXIC AND IL-12 GENE THERAPY IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER |
| Year | 2017 |
| Country | United States |
| Company sponsor | Henry Ford Health System |
| Other ID(s) | 11260 |
| Vector information | |||||||||||||
|
|||||||||||||
| Cohort1: dose level 1 | |||||||||||||
|
|||||||||||||
| Cohort2: dose level 2 | |||||||||||||
|
|||||||||||||
| Cohort3: dose level 3 | |||||||||||||
|
|||||||||||||